VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 26, 2014) - PDC Biological Health Group Corporation. (CSE:PHG) announces today that it has listed its common shares on the Frankfurt Exchange under the symbol PD8.
This European listing will enable the company to attract highly knowledgeable European investors that have a firm understanding of preventive medical devices, raise its visibility among international investors, and enhance the liquidity of its common shares.
Bernard Armani, president and chief executive officer, commented: "There is an established interest and expertise in Frankfurt in preventive medical device technology and in Frankfurt has the benefit of being located in the Eurozone. Several potential European investors have suggested that listing in Germany will make it easier for them to invest in PDC Biological Health Group Corp."
On Behalf of the Board of Directors of PDC BIOLOGICAL HEALTH GROUP CORPORATION
Bernard Armani, President and CEO
About PDC Biological Health Group Corporation
PDC's primary product, the CRT 2000 Thermographic System, is a non invasive, radiation‐free, reproducible thermographic tool that measures the temperature of predetermined skin points and analyzes such data to provide a health care practitioner with information that may be indicative of irregular body function. The CRT 2000 Thermographic System is intended for use in preventive healthcare. The CRT 2000 Thermographic System is presently ready for sale; it has obtained the CE Safety Mark (TUV) the FDA premarket notification Class I (510(k)) and is certified as a Class II medical device by the Chinese health authority (SFDA).
Neither the The Canadian Securities Exchange (CSE) nor its Regulation Services Provider (as that term is defined in the policies of the The Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements - This news release contains certain forward-looking statements, including statements regarding the business of the Company. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward looking statements, oral or written, made by itself or on its behalf except as required by law.